2.47
+0.1(+4.22%)
Currency In USD
| Previous Close | 2.37 |
| Open | 2.25 |
| Day High | 2.47 |
| Day Low | 2.25 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.87 |
| Volume | 21,742 |
| Average Volume | 36,390 |
| Market Cap | 21.63M |
| PE | -1.11 |
| EPS | -2.23 |
| Moving Average 50 Days | 2.46 |
| Moving Average 200 Days | 2.56 |
| Change | 0.1 |
If you invested $1000 in Lisata Therapeutics, Inc. (LSTA) 10 years ago, it would be worth $11.2 as of September 29, 2025 at a share price of $2.47. Whereas If you bought $1000 worth of Lisata Therapeutics, Inc. (LSTA) shares 5 years ago, it would be worth $87.59 as of September 29, 2025 at a share price of $2.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and oth
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
GlobeNewswire Inc.
Jul 31, 2025 12:00 PM GMT
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and othe
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
GlobeNewswire Inc.
Jul 17, 2025 12:00 PM GMT
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapyBASKING RIDGE, N.J. and SUBIACO, Australia, July 17, 2025 (GLOBE NEW